Cargando...
Drug repurposing against COVID-19: focus on anticancer agents
BACKGROUND: The very limited time allowed to face the COVID-19 pandemic poses a pressing challenge to find proper therapeutic approaches. However, synthesis and full investigation from preclinical studies to phase III trials of new medications is a time-consuming procedure, and not viable in a globa...
Guardado en:
| Publicado en: | J Exp Clin Cancer Res |
|---|---|
| Autores principales: | , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
BioMed Central
2020
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7214852/ https://ncbi.nlm.nih.gov/pubmed/32398164 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13046-020-01590-2 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|